NME1 / NDKA Protein & Antibody

Non-metastatic cells 1, protein (NM23A) expressed in / Nucleoside Diphosphate Kinase A

NME1 / NDKA Products

NME1 / NDKA Protein, Recombinant

Molecule	Species	Description	Cat. No
NME1/NDKA	Human	NME1/NDKA Protein, Recombinant	11615-H07E

NME1 / NDKA Antibody

Molecule	Application	Description	Cat. No
Human NME1/NDKA	WB, ELISA	NME1/NDKA Antibody, Rabbit PAb	11615-RP01
Human NME1/NDKA	WB, ELISA	NME1/NDKA Antibody, Rabbit PAb (Antigen Affinity Purified)	11615-RP02

NME1 / NDKA cDNA Clone

Molecule	Species	Description	Cat. No
NME1/NDKA	Human	Homo sapiens NME1/NDKA cDNA Clone	HG11615-M

NME1 / NDKA Related Areas

Enzyme>>Protein Kinase>>Intracellular Kinase>>NME1/NDKA

Signal Transduction>>Protein Kinase>>Intracellular Kinase>>NME1/NDKA

NME1 / NDKA Alternative Names

NME1, NDK A, NDPK-A, NDPKA, AWD, GAAD, NB, NBS, NM23, NM23-H1 [Homo sapiens]

Nme1, NDK A, NDPK-A, RP23-378I13.1, AL024257, NM23-M1, NM23A [Mus musculus]

NME1 / NDKA Background

NME1, also known as Nucleoside Diphosphate Kinase A (NDK-A), or NM23-H1, belongs to the NDK family. NM23-H1 is known to have a metastasis suppressive activity in many tumor cells. Recent studies have shown that the interacting proteins with NM23-H1 which mediate the cell proliferation, may act as modulators of the metastasis suppressor activity. The interacting proteins with NM23-H1 can be classified into 3 groups. The first group of proteins can be classified as upstream kinases of NM23-H1 such as CKI and Aurora-A/STK15. The second group of proteins acts as downstream effectors for the regulation of specific gene transcriptions, GTP-binding protein functions, and signal transduction in Erk signal cascade. The third group of proteins can be classified as bi-directionally influencing binding partners of NM23-H1. As a result, the interactions with NM23-H1 and binding partners have implications in the biochemical characterization involved in metastasis and tumorigenesis. NDKA is increased in human postmortem cerebrospinal fluid (CSF), a model of global brain insult, suggesting that measurement in CSF and, more importantly, in plasma may be useful as a biomarker of stroke. Additionally, NM23-H1 significantly reduces metastasis without effects on primary tumor size and was the first discovered metastasis suppressor gene.

NME1 / NDKA Related Studies

1. Allard L, et al. (2005) PARK7 and nucleoside diphosphate kinase A as plasma markers for the early diagnosis of stroke. Clin Chem. 51(11): 2043-51.
2. Steeg PS, et al. (2008) Clinical-translational approaches to the Nm23-H1 metastasis suppressor. Clin Cancer Res. 14(16): 5006-12.
3. Kim HD, et al. (2009) Regulators affecting the metastasis suppressor activity of Nm23-H1. Mol Cell Biochem. 329(1-2): 167-73.